Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—The<scp>MAFLD</scp>fibrosis score-Reference-Cited by-同舟云学术

Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score

Published:2023-11-20 Issue:11-12 Volume:58 Page:1234-1235
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sharpton Suzanne¹^ORCID

Affiliation:

1. Division of Gastroenterology, Hepatology and Nutrition Vanderbilt University Medical Center Nashville Tennessee USA

Abstract

LINKED CONTENTThis article is linked to Cheung et al papers. To view these articles, visithttps://doi.org/10.1111/apt.17722andhttps://doi.org/10.1111/apt.17774

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17744

Reference8 articles.

1. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

2. Noninvasive Assessment of Liver Fibrosis in NAFLD

3. Advances in non-invasive assessment of hepatic fibrosis

4. MAFLD fibrosis score: using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease;Cheung JTK;Aliment Pharmacol Ther,2023

5. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—the MAFLD fibrosis score. Authors' reply;Alimentary Pharmacology & Therapeutics;2023-11-20